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considerably in several respects including onset and duration of action, potency, predictability, pharmacokinetics, metabolism, drug interactions and cardiotoxicity. The usefulness of these drugs in humans is closely linked to these criteria, and it is therefore interesting to compare these drugs objectively in healthy volunteers as well as in atopic subjects. The potencies of the drugs are usually compared at the recommended dose but this has limitations and does not allow the objective quantification of differences in potency. The effective dose 50 (ED 50 ) method does and has not previously been used to compare second-generation H 1antihistamines. The ED 50 for such compounds is the dose that inhibits, by 50%, skin reactions induced by a challenge with a given histamine concentration.
On the basis of previous results, 1 we studied three different doses of cetirizine (2.5, 5 and 10 mg) and loratadine (10, 20 and 40 mg) in order to determine the ED 50 for each compound. We decided to use three different histamine concentrations (10, 100 and 500 mg/ml) for exploratory purposes.
PATIENTS AND METHODS

PATIENTS
Healthy asymptomatic Caucasian females between the ages of 22 and 43 years were recruited. They weighed between 45 and 75 kg and their heights were between 157 and 176 cm, respectively. Each subject gave written informed consent for participation, and was aware of being free to withdraw from the study at any time without prejudice. A medical history and examination was performed. Exclusion criteria included lactation, pregnancy (assessed by a pregnancy test) or potential pregnancy, concomitant chronic disease, known renal or hepatic insufficiency, known allergy to cetirizine, loratadine or any other piperazines and to lactose, cornstarch and cellulose; any H 1 -antihistamines within a week (astemizole within 6 weeks); ketotifen within 2 weeks; non-steroidal antiinflammatory drugs, topical and systemic corticosteroids within 2 weeks, any other treatment within 2 weeks, and participation in another study for 3 months.
The Bioethics Committee of Romania approved the protocol.
STUDY DESIGN AND TREATMENTS
This study was conducted at the Malaxa Hospital, Bucharest, Romania. A doubleblind, placebo-controlled, randomized crossover design was used. Seven singledose treatments were administered: cetirizine 2.5 mg, 5 mg and 10 mg capsules; loratadine 10 mg, 20 mg, 40 mg capsules and placebo capsules. White cream capsules were used in order to preserve the study blinding. To eliminate any significant carryover effect, there was a washout period of approximately 7 days between each treatment.
A total of 14 subjects completed all seven dosing periods and evaluations. In order to have a baseline response for each individual at each period a skin prick test (SPT) with histamine dihydrochloride in saline 10, 100 and 500 mg/ml was performed on the right forearm at 08.00. The skin reactions were transferred onto transparencies 10 min later. At 08.15 the drug was given to the subject by the investigator and swallowed with a glass of water. Cutaneous reactivity to an SPT with the three different histamine concentrations was measured 2, 4 and 6 h after drug intake (based upon the pharmacokinetics of the two drugs). The surface areas of the wheals and flares were measured by computerized planimetry. 2 Subjects were queried about side-effects I Ramboer, R Bumbacea, D Lazarescu et al.
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by asking the open question: how have you been feeling since your last visit?
QUANTITATIVE ASSESSMENT
Descriptive statistics were calculated for all ED 50 doses. For the wheal and flare surface areas both the absolute and percentage differences, with respect to the baseline value, were described (mean, median, standard deviation, minimum, maximum, and number of observations). The efficacy evaluation was based upon the recording of wheals and flares, before, and 2, 4 and 6 h after administration of the study medication, for each of three histamine concentrations. The ED 50 of cetirizine and loratadine were calculated, separately for wheals and flares, and separately for each of the three histamine concentrations. The ED 50 were derived from the mean percentage decrease in wheal and flare surface area, respectively, 2, 4, and 6 h after drug intake with respect to the measurement before intake, using linear interpolation. The results with placebo were used as the zero-concentration results for estimation of the ED 50 of both cetirizine and loratadine.
For the comparison of therapeutic doses of cetirizine and loratadine, the two treatments were compared for each histamine concentrations separately but controlled for the evaluation time. Repeated measures of variance analyses were performed. Since the percentage decrease in surface area can take negative values, no evident suitable transformation was available. Therefore, the comparison of the two treatments was also performed for each of the three evaluation times and each of the three histamine concentrations separately using the non-parametric Wilcoxon test.
RESULTS
The mean values for the surface area of wheal and flare reactions induced by histamine (10, 100, 500 mg/ml) prick tests for the different doses of cetirizine and loratadine up to 6 h are shown in Figs 1 and 2. A reduction in wheal size for all doses of drugs was observed at various time points with a maximum effect between 4 and 6 h.
The decrease in the flare size showed a greater range than the reductions in wheal size. The two drugs were effective at all doses, and at all times up to 6 h, except for loratadine 10 mg which was not significantly effective 2 h after intake. We observed considerable interindividual variability, which is typical of this kind of experiment, but did not interfere with the consistency of the results. In fact, the curves are similar to those described previously. 3, 4 The mean relative decrease in surface area are shown in Table 1 for both drugs and for the wheal and flare reactions. The 10-mg dose of cetirizine produced maximal inhibition of 96% for wheal and 92% for flare, after a challenge with histamine 10 mg/ml, 6 h after intake. The 40-mg dose of loratadine produced maximal inhibition of 92% and 89%, respectively, for the wheal and flare reactions induced by histamine 10 mg/ml, 6 h after intake.
On the basis of the mean percentage decrease of skin reactions, as observed for 14 subjects (Table 1) , the ED 50 were calculated by linear interpolation between the concentrations surrounding the ED 50 dose. The results are shown in Table 2 . For cetirizine the ED 50 for wheals were within the ranges 4.3 -4.7 mg, 2.1 -2.2 mg and 1.7 -1.9 mg, 2, 4 and 6 h after intake, respectively (depending on the histamine concentration). For loratadine, the ED 50 doses for wheals were about nine, seven or six and a half times higher than those of cetirizine after 2, 4 and 6 h, respectively.
For flares, the ED 50 showed bigger ranges, but the ratios between the ED 50 for cetirizine M Nomura, S Kida, J Yamashita et al.
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and loratadine were roughly the same. Thus doses of loratadine about seven, nine and eight times higher, respectively, than of cetirizine were needed to inhibit a flare reaction by 50%, 2 h, 4 h or 6 h after drug intake. Finally, we compared the percentage decrease in skin reactivity after therapeutic doses (10 mg) of cetirizine and loratadine. This confirmed the higher potency of cetirizine. A highly significant (P ≤ 0.001) difference is observed between the percentage decrease of wheal and flare reactions by cetirizine and loratadine for each evaluation time and each histamine concentration.
No serious adverse events were reported for the treatments in this study. Adverse events were reported in two subjects under placebo, in four subjects under cetirizine and in eight subjects under loratadine. All of these events were due to somnolence 
Mean surface area of wheal responses after epicutaneous challenge with (A) 10 mg/ml, (B) 100 mg/ml or (C) 500 mg/ml histamine, performed before and up to 6 h after a single dose of cetirizine (CTZ; 2.5, 5, 10 mg) or loratadine (Lora; 10, 20, 40 mg) or placebo in 14 healthy female adults. The standard deviation varied from 1 to 8 mm 2 for graph A, from 4 to 37 mm 2 for graph B and from 3 to 22 mm 2 for graph C.
DISCUSSION
This is the first report to quantify the differences in potency between cetirizine and loratadine using an objective method: the evaluation of the ED 50 . This technique is commonly used in animal pharmacology but is not an easy study to perform in humans: a high degree of co-operation and motivation on the part of the subjects is necessary in that they agree to seven standardized visits, which impose constraints both in terms of time and behaviour. In fact, a large series of comparative clinical pharmacology studies of H 1 -antihistamines has been published. 3 -11 In such studies, the drugs are given at the recommended doses, and the results are A, from 61 to 314 mm 2 for graph B and from 147 to 437 mm 2 surface area (%) for wheal and flare responses after epicutaneous histamine (10, 100 and  500 mg/ml) challenge, performed before and up to 6 h after a single dose of cetirizine (2.5, 5 or 10 mg), loratadine (10, 20 or  40 mg) 
Mean surface area of flare responses after epicutaneous challenge with (A) 10 mg/ml, (B) 100 mg/ml or (C) 500mg/ml histamine, performed before and up to 6 h after a single dose of cetirizine (CTZ; 2.5, 5 or 10 mg) or loratadine (Lora; 10, 20 or 40 mg) or placebo in 14 healthy female adults. The standard deviation varied from 24 to 284 mm 2 for graph
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expressed as the percentage of inhibition of histamine-induced wheal and flare reactions. Such studies do not allow quantitative comparisons between drugs. For example, Grant et al. 4 showed that terfenadine 120 mg and cetirizine 10 mg have similar inhibitory powers: 86% and 96%, respectively. On the other hand cetirizine, ebastine and loratadine at therapeutic doses of 10 mg have very different inhibition powers: 96%, 75% and 31%, respectively. With the ED 50 method we found that cetirizine was about seven to nine times more potent than loratadine for wheal and flare reactions. Such a big difference is surprising, and indicates that differences in the potency of the different H 1 -antagonists may have been underestimated in the past. This underestimation may be the result of a flaw in the conventional wheal and flare experimental approach. Using the usual histamine skin test, the most potent drugs induce inhibitions in the range 90 -100%, a result that cannot be improved. When such an inhibition is observed, it may be that the drug is potent enough to give precisely 90 -100% inhibition or that the drug is more potent, but the test cannot detect inhibition at a higher level. The only way to discriminate between these two possibilities is to reduce the dose of the drug to see whether a lower dose results in a lower level of inhibition. This is precisely what we did with cetirizine. 
In the present study, the incidence of side-effects remained low even at high doses of loratadine. If we consider the recommended doses of both drugs, that is to say 10 mg, three volunteers complained of somnolence while taking cetirizine and four while taking loratadine, the proportions to be expected in this kind of clinical pharmacology study. The small number of volunteers enrolled in this study does not allow us to reach conclusions about safety issues.
In conclusion, the ED 50 method, although not easy to perform in humans (see page 73), should be used more frequently to measure objectively the drug potency differences. Such an objective pharmacological approach is a useful tool for the chemists whose goal is to synthesize new drugs with better therapeutic indices.
